{"id":"valsartan-diovan","safety":{"commonSideEffects":[{"rate":"7–10","effect":"Dizziness"},{"rate":"2–3","effect":"Fatigue"},{"rate":"2–4","effect":"Hyperkalemia"},{"rate":"1–2","effect":"Cough"},{"rate":"1–2","effect":"Diarrhea"},{"rate":"1–2","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor subtype. By blocking angiotensin II—a potent vasoconstrictor and aldosterone-stimulating hormone—valsartan reduces peripheral vascular resistance, lowers blood pressure, and decreases cardiac workload. This mechanism also provides cardioprotective and renoprotective effects in heart failure and hypertension.","oneSentence":"Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:18.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction with left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":6558},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":"Takotsubo Cardiomyopathy","enrollment":100},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05194111","phase":"PHASE1, PHASE2","title":"Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-08-11","conditions":"Heart Failure, Heart Dysfunction","enrollment":53},{"nctId":"NCT07465679","phase":"","title":"A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-28","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":500},{"nctId":"NCT07465653","phase":"PHASE1","title":"A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-19","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":12},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":"Hypertension","enrollment":500},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT07444398","phase":"PHASE1","title":"Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial","status":"RECRUITING","sponsor":"Khawaja Danish Ali","startDate":"2026-01-01","conditions":"Decompensated Heart Failure","enrollment":130},{"nctId":"NCT06536309","phase":"PHASE4","title":"Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07","conditions":"Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis","enrollment":36},{"nctId":"NCT07417215","phase":"PHASE4","title":"The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF","status":"NOT_YET_RECRUITING","sponsor":"University Clinical Hospital Mostar","startDate":"2026-01-30","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan","enrollment":60},{"nctId":"NCT05528419","phase":"PHASE4","title":"Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-06","conditions":"Atrial Fibrillation Recurrent, Hypertension","enrollment":320},{"nctId":"NCT07376265","phase":"","title":"A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-20","conditions":"Heart Failure","enrollment":1249},{"nctId":"NCT07379788","phase":"","title":"ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling","status":"RECRUITING","sponsor":"Rehab Werida","startDate":"2025-12-25","conditions":"Heart Failure","enrollment":180},{"nctId":"NCT03872778","phase":"PHASE1, PHASE2","title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2019-05-24","conditions":"Neoplasms","enrollment":35},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT06142383","phase":"PHASE2","title":"A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-12","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT06930885","phase":"PHASE3","title":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-06-12","conditions":"Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":7713},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07347925","phase":"","title":"Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2026-01-10","conditions":"Heart Failure","enrollment":140},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT07341893","phase":"NA","title":"Sacubitril-valsartan in Patients With Heart Failure.","status":"RECRUITING","sponsor":"Damanhour University","startDate":"2025-08-01","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT06237309","phase":"PHASE2","title":"REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-11","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT07331389","phase":"PHASE1","title":"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Overweight Subject, Healthy Subjects","enrollment":111},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT07327749","phase":"PHASE4","title":"Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-10-01","conditions":"Hypertension","enrollment":59},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT05991284","phase":"PHASE4","title":"Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-29","conditions":"Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation","enrollment":84},{"nctId":"NCT03744975","phase":"PHASE2","title":"PDD in Type 2 Diabetes w/wo Diastolic Dysfunction","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":72},{"nctId":"NCT06643819","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-10-14","conditions":"Essential Hypertension","enrollment":324},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":"Hemodialysis","enrollment":100},{"nctId":"NCT07241338","phase":"PHASE4","title":"Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Jing Liu","startDate":"2025-11","conditions":"Hypertension","enrollment":104},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":62},{"nctId":"NCT04023227","phase":"PHASE4","title":"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Chagas Disease, Heart Failure","enrollment":918},{"nctId":"NCT06149104","phase":"PHASE3","title":"A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-04","conditions":"Heart Failure","enrollment":8},{"nctId":"NCT05279742","phase":"PHASE1, PHASE2","title":"Enhancing the Natriuretic Peptide System in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"Horng Chen","startDate":"2022-11-04","conditions":"Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT07192341","phase":"NA","title":"Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-09-27","conditions":"Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure","enrollment":220},{"nctId":"NCT07197372","phase":"","title":"Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-30","conditions":"ARNI, Pediatric Dilated Cardiomyopathy, ACE Inhibitor","enrollment":70},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT03508739","phase":"PHASE3","title":"Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition","status":"SUSPENDED","sponsor":"University of Pennsylvania","startDate":"2018-06-01","conditions":"Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension","enrollment":25},{"nctId":"NCT01764178","phase":"PHASE1","title":"To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2013-01-22","conditions":"Hyperlipidemia, Hypertension","enrollment":52},{"nctId":"NCT07157527","phase":"","title":"Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Left Ventricular Diastolic Function","enrollment":70},{"nctId":"NCT06704633","phase":"PHASE4","title":"Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania","status":"NOT_YET_RECRUITING","sponsor":"Martin Rohacek","startDate":"2026-01-05","conditions":"Heart Failure","enrollment":238},{"nctId":"NCT06917664","phase":"PHASE4","title":"Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-05","conditions":"Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor","enrollment":220},{"nctId":"NCT07139405","phase":"PHASE2","title":"TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT","status":"NOT_YET_RECRUITING","sponsor":"Myopharm Limited","startDate":"2026-02","conditions":"Type 2 Diabetes (T2DM)","enrollment":90},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":"Patients With Advanced Cancer Receiving Specialized Palliative Care","enrollment":97},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":"Polymorphic Ventricular Tachycardia, Heart Failure","enrollment":118},{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":"Essential Hypertension","enrollment":286},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT07088471","phase":"","title":"Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Connolly Hospital Blanchardstown","startDate":"2024-11-01","conditions":"Heart Failure and Reduced Ejection Fraction","enrollment":334},{"nctId":"NCT03738878","phase":"PHASE4","title":"Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-11-15","conditions":"Hypertension","enrollment":4},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04055428","phase":"PHASE2","title":"NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-15","conditions":"Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance","enrollment":200},{"nctId":"NCT05976230","phase":"","title":"Special Drug Use Surveillance of Entresto Tablets (Hypertension)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-04","conditions":"Hypertension","enrollment":1125},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT07023016","phase":"PHASE2, PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":"Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)","enrollment":515},{"nctId":"NCT05353166","phase":"PHASE2","title":"REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-06-30","conditions":"Heart Failure","enrollment":59},{"nctId":"NCT05170061","phase":"PHASE3","title":"24 Hour Ambulatory Cardiac Oxygen Consumption","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2013-02","conditions":"Hypertension","enrollment":26},{"nctId":"NCT03535376","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Valsartan","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT03686657","phase":"PHASE1, PHASE2","title":"Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"ARKAY Therapeutics","startDate":"2025-10-10","conditions":"Type 2 Diabetes, High Blood Pressure, Arthritis","enrollment":115},{"nctId":"NCT03928158","phase":"PHASE2","title":"LCZ696 in Advanced LV Hypertrophy and HFpEF","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2019-05-31","conditions":"Heart Failure, Essential Hypertension","enrollment":61},{"nctId":"NCT04491136","phase":"PHASE4","title":"Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-11","conditions":"Heart Failure","enrollment":201},{"nctId":"NCT03785405","phase":"PHASE3","title":"Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-02","conditions":"Heart Failure","enrollment":216},{"nctId":"NCT04164732","phase":"PHASE2","title":"Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-01-08","conditions":"Cardiomyopathy, Hypertrophic","enrollment":46},{"nctId":"NCT06625346","phase":"","title":"Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.","status":"RECRUITING","sponsor":"The Searle Company Limited Pakistan","startDate":"2024-09-28","conditions":"Hypertension","enrollment":420},{"nctId":"NCT04971720","phase":"PHASE2, PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":"Obesity, Cardiovascular Diseases, Hypertension","enrollment":160},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT06922253","phase":"PHASE1","title":"Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-12-28","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT06900803","phase":"NA","title":"Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-07","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence","enrollment":200},{"nctId":"NCT06053580","phase":"PHASE2","title":"Repurposing Valsartan May Protect Against Pulmonary Hypertension","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-02-28","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction","enrollment":60},{"nctId":"NCT05465031","phase":"PHASE4","title":"Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","status":"RECRUITING","sponsor":"Silesian Centre for Heart Diseases","startDate":"2024-04-17","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":600},{"nctId":"NCT06863987","phase":"PHASE3","title":"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02-05","conditions":"Essential Hypertension","enrollment":342},{"nctId":"NCT03988634","phase":"PHASE3","title":"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-29","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":467},{"nctId":"NCT04637152","phase":"PHASE2","title":"Sacubitril/Valsartan in Resistant Hypertension","status":"COMPLETED","sponsor":"Hospital Geral Roberto Santos","startDate":"2020-11-11","conditions":"Resistant Hypertension, Blood Pressure","enrollment":80},{"nctId":"NCT06655480","phase":"PHASE2","title":"Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2025-03-18","conditions":"HFpEF, LVDD, Myocardial Fibrosis","enrollment":50},{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT03760588","phase":"PHASE2","title":"Prevention of Cardiac Dysfunction During Breast Cancer Therapy","status":"COMPLETED","sponsor":"Torbjorn Omland","startDate":"2019-01-31","conditions":"Breast Cancer Female, Heart Failure","enrollment":138},{"nctId":"NCT04149990","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI","status":"TERMINATED","sponsor":"Jacob Moller","startDate":"2018-10-12","conditions":"Myocardial Infarction, Diastolic Dysfunction","enrollment":51},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT06716970","phase":"PHASE3","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-30","conditions":"Essential Hypertension","enrollment":810},{"nctId":"NCT06712030","phase":"PHASE3","title":"Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2025-01","conditions":"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","enrollment":114},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT06604897","phase":"","title":"Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis","startDate":"2023-01-31","conditions":"Essential Hypertension","enrollment":1405},{"nctId":"NCT04587947","phase":"NA","title":"Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study","status":"COMPLETED","sponsor":"St. Josefs-Hospital Wiesbaden GmbH","startDate":"2020-04-01","conditions":"Heart Failure Patients","enrollment":63},{"nctId":"NCT06090487","phase":"NA","title":"Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT06283420","phase":"","title":"Metabolic Response to the Initiation of Heart Failure Therapy","status":"RECRUITING","sponsor":"Vojtech Melenovsky, MD, PhD","startDate":"2024-08-23","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT05164653","phase":"PHASE4","title":"Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saga University","startDate":"2021-12-27","conditions":"Heart Failure","enrollment":400},{"nctId":"NCT02884206","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-23","conditions":"Chronic Heart Failure (CHF)","enrollment":592},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"ACUTE KIDNEY INJURY"},{"count":7,"reaction":"DYSPNOEA"},{"count":6,"reaction":"FATIGUE"},{"count":6,"reaction":"NAUSEA"},{"count":5,"reaction":"CARDIAC FAILURE"},{"count":5,"reaction":"DIZZINESS"},{"count":5,"reaction":"FALL"},{"count":5,"reaction":"HYPOTENSION"},{"count":5,"reaction":"PYREXIA"},{"count":4,"reaction":"ASTHENIA"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valsartan (Diovan)","genericName":"Valsartan (Diovan)","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}